258 related articles for article (PubMed ID: 9405046)
1. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
[TBL] [Abstract][Full Text] [Related]
2. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
3. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.
Barski OA; Gabbay KH; Bohren KM
Biochemistry; 1996 Nov; 35(45):14276-80. PubMed ID: 8916913
[TBL] [Abstract][Full Text] [Related]
4. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156
[TBL] [Abstract][Full Text] [Related]
5. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
6. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
7. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors.
Ehrig T; Bohren KM; Prendergast FG; Gabbay KH
Biochemistry; 1994 Jun; 33(23):7157-65. PubMed ID: 8003482
[TBL] [Abstract][Full Text] [Related]
9. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
10. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
El-Kabbani O; Old SE; Ginell SL; Carper DA
Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde reductase: the role of C-terminal residues in defining substrate and cofactor specificities.
Rees-Milton KJ; Jia Z; Green NC; Bhatia M; El-Kabbani O; Flynn TG
Arch Biochem Biophys; 1998 Jul; 355(2):137-44. PubMed ID: 9675019
[TBL] [Abstract][Full Text] [Related]
12. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of human aldehyde reductase: characterization of the active site pocket.
Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
[TBL] [Abstract][Full Text] [Related]
14. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A.
Howard EI; Sanishvili R; Cachau RE; Mitschler A; Chevrier B; Barth P; Lamour V; Van Zandt M; Sibley E; Bon C; Moras D; Schneider TR; Joachimiak A; Podjarny A
Proteins; 2004 Jun; 55(4):792-804. PubMed ID: 15146478
[TBL] [Abstract][Full Text] [Related]
15. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C
J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461
[TBL] [Abstract][Full Text] [Related]
16. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.
Dhagat U; Endo S; Hara A; El-Kabbani O
Bioorg Med Chem; 2008 Mar; 16(6):3245-54. PubMed ID: 18165015
[TBL] [Abstract][Full Text] [Related]
18. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
[TBL] [Abstract][Full Text] [Related]
19. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
Steuber H; Heine A; Podjarny A; Klebe G
J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
[TBL] [Abstract][Full Text] [Related]
20. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase.
Rondeau JM; Tête-Favier F; Podjarny A; Reymann JM; Barth P; Biellmann JF; Moras D
Nature; 1992 Jan; 355(6359):469-72. PubMed ID: 1734286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]